

Press Release – Ecully, 28th of June 2019

Seqens Cosmetics strengthens the traceability of its organic active ingredients by authenticating plant species using DNA tests.

Since May 2019, all organic actives produced by Seqens Cosmetics will be traced on the blockchain (ACT4s.com), which makes it possible to guarantee COSMOS compliance in real time, from the plant raw material to the finished product.

In addition to this full transparency approach, Seqens Cosmetics has decided to use DNA Gensee to guarantee the authenticity of the plant species used in their organic active ingredients by using DNA tests.

“We will start by ensuring the authenticity of the organic buckwheat contained in Cell’Intact™; our ambition is to gradually extend DNA testing to all plant species used in the manufacture of our organic active ingredients, in order to assure our customers of the authenticity of our raw materials”, says Marie-Alex Premier, Vice-President of the Cosmetics Division.

“The genetic analyses carried out by DNA Gensee will enable Seqens to guarantee to its customers the authenticity of their botanical raw materials. This is an extra step towards the transparency demanded by the cosmetic market”. Nicole Giraud President, DNA Gensee.

SEQENS

COSMETICS

About SEQENS

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering custom-made products and solutions to its customers.

Unique expertise to develop and produce highly complex molecules

Seqens' mission is to bring R&D and industrial performance to our clients' projects with a unique skill set and a broad continuum of technologies.

Science is its core business

Seqens operates 24 industrial plants and 3 R&D centers in Europe, North America and Asia. More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production.

An integrated partner in pharmaceutical synthesis and specialty ingredients

In the pharmaceutical industry, Seqens supports its customers for the development, scale-up and manufacturing of drug substances from preclinical through to commercial phase and offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries such as healthcare, electronics, cosmetics, food and homecare.


Entrepreneurship, reliability and responsibility

Driven by a culture of excellence and a strong entrepreneurial spirit, the 3,200 SEQENS employees are committed to providing our customers with the highest level of service and high-quality products. SEQENS is committed to developing its business sustainably and responsibly and continuously improving its SD-CSR program (Sustainable Development and Corporate Social Responsibility).

For more information about www.seqens.com

Contact SEQENS: Aline Rancony Aline.rancony@seqens.com

(+33) 6 79 18 53 92



CONTINUUM OF PROGRESS

SEQENS
www.seqens.com

With capital of 35,232,819.63 euros - 21 chemin de la Sauvegarde "21 Ecully Parc" - CS 33167 69134 ECULLY Cedex - 444 465 736 RCS Lyon